NextCure, Inc., a Delaware corporation, entered into an Agreement and Plan of Merger and Reorganization by and among the Company, Avere Therapeutics, Inc., a…

NextCure, Inc. (NXTC) filed an SEC Form 8-K — Regulation FD Disclosure. Item 7.01 Regulation FD Disclosure As previously disclosed, on July 14, 2026, NextCure, Inc., a Delaware corporation (the “Company”), entered into an Agreement and Plan of Merger and Reorganization (the “Merger Agreement”) by and among the Company, Avere Therapeutics, Inc., a Del

Event · Dividend
Kind
special
Frequency
one-time
Record date
December 8, 2026
Payable
December 14, 2026

Facts are quoted from the filing text and checked against it.

Original reporting
Published Nov 20, 2026, 9:20 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 20, 2026, 9:23 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefMergers & acquisitions
Primary signal
$NXTC
Neutral
medium confidence
Mentioned
$NXTC
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$NXTCNeutralMed
01

Why it matters

The key tradable element is the scheduled CVR distribution timeline tied to the first effective time, which can affect merger-completion probability and the perceived value of contingent legacy-asset proceeds.

02

Market read

Defines near-term corporate-event dates and CVR economics that can drive trading around merger progression and contingent value expectations.

03

What to watch

Traders should focus on the upcoming Form S-4/proxy details for deal terms, CVR valuation assumptions, and any regulatory or shareholder approval conditions that could shift the effective time.

Relevance 7/10Novelty 6/10Timing: record date Dec 8, 2026, distribution expected Dec 14, 2026, contingent on first effective time

Background

NextCure filed an 8-K (Item 7.01) describing merger agreement mechanics with Avere and announcing the record and expected distribution dates for a CVR-linked pre-closing distribution.

Company-level read

Ticker impact

$NXTCNeutralMedium confidence
Context

NextCure disclosed a merger with Avere and set a Dec 8, 2026 record date and Dec 14 distribution date for a CVR-linked pre-closing distribution.

Expected impact

Likely choppy trading as investors price merger completion risk and the value of the CVR contingent on legacy-asset monetization.

Evidence & confidence

The filing is an SEC EDGAR 8-K detailing merger structure and a scheduled CVR distribution timeline, which can affect near-term valuation and risk perception even without deal price terms in the excerpt.

Market effects

Biopharma M&A structures using CVRs can influence how investors value pre-merger legacy asset monetization risk across small-cap biotech deals.

Limited, primarily relevant to US small-cap biotech and merger-arb participants.

Low, as the disclosure is company-specific and not tied to a global macro or cross-border regulatory shock.

Counterpoint

The CVR is contingent on future monetization of legacy assets, so the distribution timeline may not translate into meaningful near-term equity value if expected proceeds are low or delayed.

Key entities

  • NextCure, Inc.

    Subject of the 8-K, entering a merger agreement with Avere and setting CVR pre-closing distribution record and expected distribution dates.

  • Avere Therapeutics, Inc.

    Counterparty in the merger agreement referenced in NextCure’s filing.

Related articles

$NXTCHigh

NextCure, Inc. (NXTC): Reports Third Quarter 2026 Financial Results

NextCure, Inc. (NXTC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ​ NextCure Provides Business Update and Reports Third Quarter 2026 Financial Results ​ – Advancing Toward Stockholder Approval of Proposed Merger with Avere Therapeutics Supported by Approximately $820 Million of Committed Financing – S-4 Declared Effective by SEC; S

$NXTCMedAI 8/10

RTW Bio's Avere To Merge With NextCure

RTW Biotech Opportunities said its portfolio company Avere Therapeutics will merge with NextCure Inc. in an all-stock deal expected to close by year-end. The combined firm will trade on Nasdaq as Avere Therapeutics under AVRX. Avere plans $820M in private placements, including $5.9M from Avere, to fund AVR-001 Phase 2b psoriasis, Phase 3 psoriasis, and Phase 2b ulcerative colitis.

$NXTCMedAI 8/10

Avere Therapeutics to merge with NextCure Inc.

RTW Biotech Opportunities said private portfolio company Avere Therapeutics will go public via an all-stock reverse merger with NextCure Inc., expected by year-end. Avere plans $320 million and $500 million private placements totaling $820 million. The combined company will trade on Nasdaq as Avere Therapeutics, Inc. under ticker AVRX, funding AVR-001 through psoriasis Phase 2b and Phase 3, and ulcerative colitis Phase 2b.

$NXTCMed

NextCure, Inc. (NXTC): Reports Second Quarter 2026 Financial Results

NextCure, Inc. (NXTC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 NextCure Provides Business Update and Reports Second Quarter 2026 Financial Results ​ – Announced Proposed Merger with Avere Therapeutics – Preserving Capital in Support of Merger Closing; Continuing Clinical Transition and Legacy Asset Activities ​ BELTSVILLE, MD –